Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

20202,703 citationsJournal Articlegreen Open Access

Authors

Edward E. Walsh · University of Rochester

Robert W. Frenck · University of Rochester

Ann R. Falsey · University of Rochester

Nicholas Kitchin · University of Rochester

Judith Absalon · University of Rochester

Alejandra Gurtman · University of Rochester

Stephen Lockhart ·

Abstract

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Vaccine Coverage and Hesitancy Viral gastroenteritis research and epidemiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 25, pp. 2439-2450

DOI: 10.1056/nejmoa2027906

Field-Weighted Citation Impact: 58.71